India Immuno-Oncology Drugs Market, by Drug Type (Immune Checkpoint Inhibitors (Nivolumab, Atezolimumab, Pembrolizumab, Durvalumab), Monoclonal Antibodies (Rituximab, Trastazumab, Bevacizumab , Nimotuzumab, Pertuzumab, Ado-Trastuzumab Emtansine ), and Can

India Immuno-Oncology Drugs Market, by Drug Type (Immune Checkpoint Inhibitors (Nivolumab, Atezolimumab, Pembrolizumab, Durvalumab), Monoclonal Antibodies (Rituximab, Trastazumab, Bevacizumab , Nimotuzumab, Pertuzumab, Ado-Trastuzumab Emtansine ), and Cancer Vaccines (Gardasil, Cervarix), by Cancer Type (Lung Cancer, Blood Cancer, Breast Cancer, Ovarian Cancer, Cervical Cancer, Colorectal Cancer, Stomach Cancer, Head & Neck Cancer, and Others), and by Distribution Channel (Online Pharmacies, Retail Pharmacies, and Hospital Pharmacies) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Immuno-Oncology also known as cancer immunotherapy, is a form of cancer treatment that utilizes immune system of the body to manage, prevent, and destroy cancer. Immuno-oncologists are growing and becoming a part of cancer care group by rapidly increasing the cancer care area. The researchers did study on how to attack cancer by the immune system. Some of them work in labs on creating new treatments and some of them interact between the immune system and cancer cells.
India immuno-oncology drugs market is estimated to be valued at US$ 265 Mn in 2021 and is expected to increase to US$ 550 Mn by 2028, exhibiting a CAGR of 13.1% over the forecast period.
Market Dynamics
The rising incidence of cancer, introduction of novel immuno-oncology therapies with lesser side effects, increasing government engagement to increase cancer diagnosis, and increasing adoption of inorganic growth strategies such as mergers, acquisitions, partnerships, and collaborations by key players operating in the market are the major factors that are expected to drive the growth of the Indian immuno-oncology drugs market over the forecast period.
According to the National Cancer Registry Programme (NCRP), India, one woman dies of cervical cancer every 8 minutes in India. For every 2 women newly diagnosed with breast cancer, one woman dies of it in India. Furthermore, as many people die every day due to tobacco-related cancer diseases in India. Tobacco (smoked and smokeless) use accounted for around 317,928 deaths in men and women, in 2018.
Moreover, The WHO also suggested that people with low and middle income countries should have necessary data for cancer policies because of lack of awareness for treatment availability.
Key features of the study:
This report provides an in-depth analysis of the India immuno-oncology drugs market provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the India immuno-oncology drugs market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as a part of this study include Amgen Inc., F. Hoffmann-La Roche AG., Intas Pharmaceuticals Ltd., AstraZeneca plc, Mylan N.V., Dr. Reddy's Laboratories, Bristol - Myers Squibb, Merck & Co., Inc., BIOCAD-Biotechnology company, Reliance Life Sciences, Biocon Limited, and Hetero Drugs Limited
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The India immuno-oncology drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the India immuno-oncology drugs market
Detailed Segmentation:
India Immuno-Oncology Drugs Market, Drug Type:
Immune Checkpoint Inhibitors
Nivolumab
Atezolimumab
Pembrolizumab
Durvalumab
Monoclonal Antibodies
Rituximab
Trastazumab
Bevacizumab
Nimotuzumab
Pertuzumab
Ado-Trastuzumab Emtansine
Cancer Vaccines
Gardasil
Cervarix
India Immuno-Oncology Drugs Market, Cancer Type:
Lung cancer
Blood cancer
Breast cancer
Ovarian cancer
Cervical cancer
Colorectal cancer
Stomach cancer
Head & Neck cancer
Others
India Immuno-Oncology Drugs Market, Distribution Channel:
Online Pharmacies
Retail Pharmacies
Hospital Pharmacies
Company Profiles:
Amgen, Inc. *
Company highlights
Product Portfolio
Key Highlights
Financial performance
Strategies
F. Hoffmann-La Roche AG.
Intas Pharmaceuticals Ltd.
AstraZeneca plc
Mylan N.V.
Dr. Reddy's Laboratories
Bristol - Myers Squibb
Merck & Co., Inc.
BIOCAD-Biotechnology company
Reliance Life Sciences
Biocon Limited
Hetero Drugs Limited
“*” marked represents similar segmentation in other categories in the respective section.